الفهرس 
Introduction and aim of the studyOnly 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
Much in our basic understanding of the biology of myeloma has occurred in recent years. With this knowledge, we have expanded our options of drugs that are available to patients with this disease. The effect of this agents has been tested and has produced encouraging results. Although only thalidomide and bortezomib have produced objective responses in MM, most of the other novel agents were effective in stabilizing the disease Aim of the work:This study aims at discussing myeloma as regards diagnosis and different treatment modalities with concentration on novel therapies or targeted therapies. Conclusions: Thalidomide was used successfully as a single agent, combined with dexamethasone, and with other chemotherapeutic agents. Bortezomib has established single-agent efficacy in the treatment of relapsed and refractory MM. In the future, we could select cocktails of targeted therapies to develop next-generation, more potent, and less toxic therapies.